A large study published in JAMA Network Open found that many patients with unexplained electrolyte abnormalities would go on to be diagnosed with eating disorders.
A recent study found the drug combination lenalidomide + rituximab is a durable, effective and safe alternative to the standard regimen combining rituximab and chemotherapy.
The treatment is approved for patients who have a moderate to high risk of recurrence, following nephrectomy or nephrectomy accompanied by surgical resection of metastatic lesions.
